Deep insights in China and US
Successful investment track records across private equity and credit
Seasoned investor and advisor
Deep insights in China and US
Successful investment track records across private equity and credit
About Us
Experience,expertise and judgement matter
Investing in China and US/China cross border settings is hard. We know this because we have been in the trenches. The risks are huge, so are the rewards.
Now more than ever, cross border deals are challenging as geopolitical situations worsen on both sides. Experience, expertise and judgement matter in times of great complexity and confusion.
Who We are
LionRock Asia is comprised of seasoned investment and financial professionals with more than 20 years of exprience in private equity investment and in cross border M&A.
LionRock Asia team members have developed deep business insights in both Chinese and US markets and built successful investment track records across private equity, credit and distressed industries.
LionRock Asia is skilled in private market investments, real estate, distressed debt, and cross border M&A.
Selected Transaction Experience
US:
Commercial real estate investments in multifamily, condo, office, hotel sectors; Investment programs with leading private equity and credit managers including Golub Capital, Crescent Capital and Vivo Capital; Investments in Radiology Partners, Sciclone Pharma (took private from Nasdaq)
China:
Credit Pharma (pre IPO), New China Life (1336 HKSE, 601336 SHSE), Dihon Pharma (sold to Bayer), AutoNavi (Nasdaq listed sold to Alibaba), Bitauto (Nasdaq listed sold to Tencent), Anton Oil (3337 HKSE), PPTV (sold to Suning), Hybio Pharma (300199 SZSE)
Services
LionRock Asia provides financial advisory services to international clients who want to invest in China, and to Chinese clients who plan to expand overseas.
- Business consulting
- Investment advisory
- M&A